86.86 0.00 (0.00%)
After hours: 5:15PM EDT
|Bid||85.20 x 900|
|Ask||86.89 x 1200|
|Day's Range||85.36 - 86.94|
|52 Week Range||78.29 - 100.15|
|Beta (3Y Monthly)||0.69|
|PE Ratio (TTM)||24.53|
|Earnings Date||May 23, 2019|
|Forward Dividend & Yield||2.00 (2.20%)|
|1y Target Est||103.28|
While gurus hold positions in these companies, the share price and returns continue to fall. The share price of $63 is 20.93% below its 52-week high and 4.36% above its 52-week low. The return on equity of 25.50% and return on assets of 8.29% are outperforming 79% of companies in the Drug Manufacturers - Major industry.
Intuitive Surgical (NASDAQ:ISRG) stock has started off 2019 in great fashion with back-to-back FDA approvals. In February, the U. S. FDA granted clearance for Ion, and in March it cleared da Vinci SP for certain transoral ear, nose, and throat procedures.Source: Jon Fingas via Flickr (Modified)There have been concerns over big tech firms like Alphabet (NASDAQ:GOOGL) (NASDAQ:GOOG) entering the space , but ISRG stock has decidedly shaken off those worries. It's also shaken off competition from other medical-device companies. * 7 Healthy Dividend Stocks to Buy for Extra Stability In 2019, ISRG stock has outperformed the competition--namely, Medtronic PLC (NYSE:MDT)--handily. MDT made a play to enter the space via its acquisition of Mazor Robotics last fall. Maybe MDT finally caught a glimpse into the future and realized it was going to fall behind without a drastic move in the robotics space. But this is Intuitive's court, and Medtronic is playing catch up.InvestorPlace - Stock Market News, Stock Advice & Trading TipsThe performance of ISRG stock says it all. Year-to-date, ISRG stock is up 10.5% and MDT is down 7.5%. Over the past five years, the outperformance is even more stark, proving that the market rewards innovation. ISRG stock is up an astounding 1342% during that period (as of Apr. 17), versus MDT's gain of just 48%. New Approvals Boost ISRG StockThe Ion endoluminal system has changed lung-cancer diagnosis. Doctors can now conduct minimally invasive biopsies in the peripheral lung. With the Ion system's flexible biopsy needle (called the Flexision Biopsy Needle), ISRG's technology can now access small, difficult locations in lung lesions and improve doctors' abilities to make a lung cancer diagnosis.We know that early diagnosis can save lives, and ISRG's robotic-assisted system shows how effective ISRG is in developing innovative, minimally invasive solutions and how it is extending its focus beyond surgery.The second milestone for Intuitive came on the heels of the approval of Ion; ISRG's da Vinci surgical system was approved for use in certain transoral ear,nose and throat procedures in adults. Ion provides surgeons with the ability to access deep and narrow tissue in the body through just a single, small incision.Ion utilizes a multi-jointed, wristed instruments and a fully wristed 3D HD camera. There are countless YouTube videos worth watching of the system assisting surgeons, making operations less invasive and more efficient.Ion is groundbreaking. ISRG Stock Has Momentum From ISRG's Strong Fourth QuarterISRG had an indisputably strong Q4, as its revenue rose 17% year-over-year, crossing the billion-dollar mark. The revenue jump was driven by increases in both procedures and systems sales.During the quarter, instrument and accessory revenue jumped 18% to over half a billion dollars. The volume of Da Vinci procedures grew 19% YoY. After the FDA approval for the product's use in ear, nose and throat procedures in adults this year, investors can expect to see sustained growth, propelled by new applications for the company's core da Vinci technology.In Q4, ISRG shipped 290 da Vinci Surgical Systems compared to 216 in Q4 of 2017. Not only is there more demand for the product, but surgeons are also using it more often. Worldwide, the number of da Vinci procedures grew approximately 19% year-over-year. Expect ISRG to keep posting double-digit growth figures in those areas. ISRG Stock Will Continue to RiseISRG continues to be the leader of robotic-assisted, minimally invasive surgery. The performance of ISRG stock has been wonderful and will continue to bolster investors' portfolios.ISRG's fundamentals look excellent, and the significant momentum behind the rise of ISRG stock should continue. Demand for its da Vinci technology doesn't show any sign of slowing, as the rapid growth of the elderly population increases demand for surgical procedures.Expect continued growth in the number of shipments of the da Vinci surgical system and further FDA approvals of new procedures assisted by ISRG's products.As of this writing, Luce Emerson did not hold a position in any of the aforementioned securities. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 5 Dividend Stocks Perfect for Retirees * 7 Reasons the Stock Market Rally Isn't Over Yet * 10 S&P 500 Stocks to Weather the Earnings Storm Compare Brokers The post Intuitive Surgical Stock Is the Best MedTech Company to Buy and Hold appeared first on InvestorPlace.
Medical device companies like Abbott, Medtronic and Tandem Diabetes are jockeying for a piece of the diabetes treatment market, which could be worth north of $2 trillion by 2030.
April 17, 2019 - Medtronic plc (MDT) today released new data on endovascular repair of abdominal aortic aneurysm (AAA) patients with the Endurant(TM) II/IIs stent graft system in combination with Heli-FX(TM) EndoAnchor(TM) implants and for the Valiant Navion(TM) thoracic stent graft system for thoracic endovascular repair (TEVAR). The data presented at the Charing Cross Symposium in London expands on the commitment to treat increasingly challenging aortic anatomies.
April 17, 2019 - Medtronic plc (MDT) today announced five-year outcomes from the VeClose Extension Study. The new data demonstrate durable and consistent long-term outcomes of the Medtronic VenaSeal(TM) Closure System in treating patients with chronic venous disease. The VeClose Extension Study is a follow-on study with the purpose of evaluating long-term outcomes at five years post-treatment with the VenaSeal Closure System.
The outcomes of the study demonstrates that patients on TDD along with CMM witnessed some major benefits compared to those on CMM alone.
Minnesota is one of 19 states that have proposed legislation called Fair Repair. The act, also referred to as Right to Repair in some states, would require electronics manufacturers to make their repair manuals, tools and parts available for purchase by consumers and repair shops.
The outcomes of the study, conducted by Medtronic (MDT), demonstrates that patients on TDD along with CMM witnessed some major benefits compared to those on CMM alone.
Medtronic's (MDT) Guardian Connect system can now be accessed via a Blue Cross and Blue Shield of Minnesota member's pharmacy benefit.
Positive HVAD LATERAL TM Study Results Also Now Published in The Journal of Heart and Lung Transplantation DUBLIN and ORLANDO, Fla. - April 8, 2019 - Medtronic plc (NYSE:MDT) today announced data showing ...
Medtronic's (MDT) latest data is expected to boost top-line contributions from the HeartWare HVAD System within the CRHF suite.
Savings Are Driven by Fewer Inpatient Visits, Shorter Inpatient Length of Stay, and Fewer Emergency Department Visits DUBLIN - April 8, 2019 - Medtronic plc (NYSE:MDT) today announced results of a study ...
Company Has Initiated a Post-Approval Study of Heart Failure Management Best Practices to Further Demonstrate Improved Patient Outcomes DUBLIN and ORLANDO, Fla. - April 5, 2019 - Medtronic plc (NYSE:MDT) ...
Ecolab Inc. is the latest large employer to come out in support of the Equality Act, which would extend federal civil rights protections to lesbian, gay, bisexual, transgender and queer (LGBTQ) employees.
The MedTech Innovation Accelerator is a collaborative initiative on part of Medtronic (MDT) to foray into the Chinese med-tech innovation market via venture investments, incubation and acceleration.
Like everyone else, elite investors make mistakes. Some of their top consensus picks, such as Amazon, Facebook and Alibaba, have not done well in Q4 due to various reasons. Nevertheless, the data show elite investors' consensus picks have done well on average over the long-term. The top 15 S&P 500 stocks among hedge funds at […]
Medtronic is launching an accelerator for early-stage medical-technology companies that will be based in Shanghai.
Want to participate in a research study? Help shape the future of investing tools and earn a $60 gift card! We've lost count of how many times insiders have accumulatedRead More...